NASDAQ:IMUX Immunic (IMUX) Stock Price, News & Analysis $0.71 0.00 (0.00%) As of 09:51 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Immunic Stock (NASDAQ:IMUX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Immunic alerts:Sign Up Key Stats Today's Range$0.70▼$0.7250-Day Range$0.66▼$1.2852-Week Range$0.56▼$2.11Volume145,916 shsAverage Volume964,004 shsMarket Capitalization$68.32 millionP/E RatioN/ADividend YieldN/APrice Target$11.60Consensus RatingBuy Company Overview Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York. Read More Immunic Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreIMUX MarketRank™: Immunic scored higher than 52% of companies evaluated by MarketBeat, and ranked 546th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingImmunic has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageImmunic has only been the subject of 4 research reports in the past 90 days.Read more about Immunic's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Immunic are expected to grow in the coming year, from ($0.94) to ($0.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunic is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunic is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunic has a P/B Ratio of 3.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Immunic's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.14% of the float of Immunic has been sold short.Short Interest Ratio / Days to CoverImmunic has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Immunic has recently increased by 75.06%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmunic does not currently pay a dividend.Dividend GrowthImmunic does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.14% of the float of Immunic has been sold short.Short Interest Ratio / Days to CoverImmunic has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Immunic has recently increased by 75.06%, indicating that investor sentiment is decreasing significantly. News and Social Media2.7 / 5News SentimentN/A News SentimentImmunic has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Immunic this week, compared to 4 articles on an average week.Search Interest35 people have searched for IMUX on MarketBeat in the last 30 days. This is an increase of 192% compared to the previous 30 days.MarketBeat Follows6 people have added Immunic to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Immunic insiders have bought more of their company's stock than they have sold. Specifically, they have bought $28,150.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 4.60% of the stock of Immunic is held by insiders.Percentage Held by Institutions51.82% of the stock of Immunic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immunic's insider trading history. Receive IMUX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunic and its competitors with MarketBeat's FREE daily newsletter. Email Address IMUX Stock News HeadlinesImmunic, Inc. (NASDAQ:IMUX) Chairman Duane Nash Purchases 20,000 SharesJune 17, 2025 | insidertrades.comImmunic CEO discusses Phase 2 multiple sclerosis study success - ICYMIJune 28, 2025 | proactiveinvestors.comTrump Makes Major Crypto AnnouncementPay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift all boats equally. They're wrong. One project stands to benefit more than any other – not by accident, but seemingly by design. July 3 at 2:00 AM | Crypto 101 Media (Ad)Immunic reveals long-term data supporting potential of MS drug vidofludimus calciumJune 24, 2025 | proactiveinvestors.comImmunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple SclerosisJune 24, 2025 | prnewswire.comImmunic showcases MS drug data at BIO International Convention in Boston - ICYMIJune 21, 2025 | proactiveinvestors.comImmunic Post-Readout: Reiterating Strong Buy As Big Drop Appears UnwarrantedJune 9, 2025 | seekingalpha.comImmunic completes Phase 3 multiple sclerosis trial enrollment - ICYMIJune 7, 2025 | proactiveinvestors.comSee More Headlines IMUX Stock Analysis - Frequently Asked Questions How have IMUX shares performed this year? Immunic's stock was trading at $1.00 at the start of the year. Since then, IMUX shares have decreased by 28.7% and is now trading at $0.7130. View the best growth stocks for 2025 here. How were Immunic's earnings last quarter? Immunic, Inc. (NASDAQ:IMUX) issued its earnings results on Thursday, May, 15th. The company reported ($0.25) EPS for the quarter, meeting analysts' consensus estimates of ($0.25). How do I buy shares of Immunic? Shares of IMUX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Immunic own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immunic investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Alibaba Group (BABA), CrowdStrike (CRWD), Viking Therapeutics (VKTX), BioXcel Therapeutics (BTAI) and Aldeyra Therapeutics (ALDX). Company Calendar Last Earnings5/15/2025Today7/03/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMUX CIK1280776 Webwww.immunic-therapeutics.com Phone(332) 255-9818Fax858-673-6843Employees70Year FoundedN/APrice Target and Rating Average Stock Price Target$11.60 High Stock Price Target$28.00 Low Stock Price Target$5.00 Potential Upside/Downside+1,526.9%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($1.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$100.51 million Net MarginsN/A Pretax MarginN/A Return on Equity-326.95% Return on Assets-181.34% Debt Debt-to-Equity RatioN/A Current Ratio0.74 Quick Ratio0.74 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.20 per share Price / Book3.57Miscellaneous Outstanding Shares95,820,000Free Float91,410,000Market Cap$68.32 million OptionableOptionable Beta1.49 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:IMUX) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredA grave, grave error.President Donald Trump made headlines last month with a staggering claim. He stated that since taking offic...Porter & Company | SponsoredThe Pentagon just made a National Security move...This "awesome resource" could power America for 30,000 years... We sent one of our smartest researchers.......Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.